The PulseCalendarHealth BlueprintAbout

Explorer

Longevity Clinics MapLongevity Investors MapWearables & Nearables Map

Academy

CoursesMy Learning

Back to Longevity News

News summary

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.

Source: FierceBiotech - All • Published: 17 Sept 2026, 06:27

Summarized by Masters of Longevity from FierceBiotech - All.

A deal-focused business article that examines why a South Korean biopharma added another preclinical Parkinson’s asset to its pipeline and what the pact means for its strategy.

SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.
Key Takeaways
  • SK Biopharmaceuticals agreed a deal worth $314.8 million to acquire a second preclinical Parkinson's therapy.
  • The transaction is with another South Korean drug developer and adds a Parkinson's asset to SK's pipeline.
  • The agreement includes upfront and contingent payments structured across development and commercialization milestones.
Read the full article at FierceBiotech - All ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.